Pesquisa | BVS Violência e Saúde

1.

B-cell non-Hodgkin lymphomas.

Silkenstedt, Elisabeth; Salles, Gilles; Campo, Elias; Dreyling, Martin.

Lancet ; 403(10438): 1791-1807, 2024 May 04.

Artigo em Inglês | MEDLINE | ID: mdl-38614113

2.

Mantle cell lymphoma-Update on molecular biology, prognostication and treatment approaches.

Silkenstedt, Elisabeth; Dreyling, Martin.

Hematol Oncol ; 41 Suppl 1: 36-42, 2023 Jun.

Artigo em Inglês | MEDLINE | ID: mdl-37294961

3.

Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimus.

Moosburner, Marie; Alibegovic, Lamija; Hasselmann, Korbinian; Gaiderov, Anton; Hildebrand, Johannes; Philippou-Massier, Julia; Blum, Helmut; Fischer, Luca; Dreyling, Martin; Silkenstedt, Elisabeth.

Hematol Oncol ; 41(5): 858-868, 2023 Dec.

Artigo em Inglês | MEDLINE | ID: mdl-37300279

4.

The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysis.

Fischer, Luca; Jiang, Linmiao; Bittenbring, Joerg Thomas; Huebel, Kai; Schmidt, Christian; Duell, Johannes; Metzner, Bernd; Krauter, Juergen; Glass, Bertram; Huettmann, Andreas; Schaefer-Eckart, Kerstin; Silkenstedt, Elisabeth; Klapper, Wolfram; Hiddemann, Wolfgang; Unterhalt, Michael; Dreyling, Martin; Hoster, Eva.

Ann Hematol ; 102(10): 2791-2801, 2023 Oct.

Artigo em Inglês | MEDLINE | ID: mdl-37552322

5.

Mantle cell lymphoma - advances in molecular biology, prognostication and treatment approaches.

Silkenstedt, Elisabeth; Linton, Kim; Dreyling, Martin.

Br J Haematol ; 195(2): 162-173, 2021 10.

Artigo em Inglês | MEDLINE | ID: mdl-33783838

6.

Mantle cell lymphoma-Advances in molecular biology, prognostication and treatment approaches.

Silkenstedt, Elisabeth; Dreyling, Martin.

Hematol Oncol ; 39 Suppl 1: 31-38, 2021 Jun.

Artigo em Inglês | MEDLINE | ID: mdl-34105823

7.

Biological and Clinical Determinants Shaping Heterogeneity in Mantle Cell Lymphoma.

López, Cristina; Silkenstedt, Elisabeth; Dreyling, Martin; Beà, Silvia.

Blood Adv ; 2024 May 15.

Artigo em Inglês | MEDLINE | ID: mdl-38748869

8.

The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.

Fischer, Luca; Jiang, Linmiao; Dürig, Jan; Schmidt, Christian; Stilgenbauer, Stephan; Bouabdallah, Krimo; Solal-Celigny, Philippe; Scholz, Christian W; Feugier, Pierre; de Wit, Maike; Trappe, Ralf Ulrich; Hallek, Michael; Graeven, Ullrich; Hänel, Mathias; Hoffmann, Martin; Delwail, Vincent; Macro, Margaret; Greiner, Jochen; Giagounidis, Aristoteles A N; Dargel, Beate; Durot, Eric; Foussard, Charles; Silkenstedt, Elisabeth; Weigert, Oliver; Pott, Christiane; Klapper, Wolfram; Hiddemann, Wolfgang; Unterhalt, Michael; Hoster, Eva; Ribrag, Vincent; Dreyling, Martin.

Leukemia ; 38(6): 1307-1314, 2024 Jun.

Artigo em Inglês | MEDLINE | ID: mdl-38678093

9.

[Aggressive lymphoma (DLBCL, MCL) - what's new?] / Aggressive Lymphome (DLBCL, MCL) was ist neu?

Silkenstedt, Elisabeth; Dreyling, Martin.

Dtsch Med Wochenschr ; 147(22): 1449-1456, 2022 Nov.

Artigo em Alemão | MEDLINE | ID: mdl-36318907

10.

PARP14 is a novel target in STAT6 mutant follicular lymphoma.

Mentz, Michael; Keay, William; Strobl, Carolin Dorothea; Antoniolli, Martina; Adolph, Louisa; Heide, Michael; Lechner, Axel; Haebe, Sarah; Osterode, Elisa; Kridel, Robert; Ziegenhain, Christoph; Wange, Lucas Esteban; Hildebrand, Johannes Adrian; Shree, Tanaya; Silkenstedt, Elisabeth; Staiger, Annette M; Ott, German; Horn, Heike; Szczepanowski, Monika; Richter, Julia; Levy, Ronald; Rosenwald, Andreas; Enard, Wolfgang; Zimber-Strobl, Ursula; von Bergwelt-Baildon, Michael; Hiddemann, Wolfgang; Klapper, Wolfram; Schmidt-Supprian, Marc; Rudelius, Martina; Bararia, Deepak; Passerini, Verena; Weigert, Oliver.

Leukemia ; 36(9): 2281-2292, 2022 09.

Artigo em Inglês | MEDLINE | ID: mdl-35851155

11.

Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells.

López-Guerra, Mónica; Xargay-Torrent, Sílvia; Fuentes, Patricia; Roldán, Jocabed; González-Farré, Blanca; Rosich, Laia; Silkenstedt, Elisabeth; García-León, María J; Lee-Vergés, Eriong; Giménez, Neus; Giró, Ariadna; Aymerich, Marta; Villamor, Neus; Delgado, Julio; López-Guillermo, Armando; Puente, Xose S; Campo, Elias; Toribio, María L; Colomer, Dolors.

Oncogene ; 39(6): 1185-1197, 2020 02.

Artigo em Inglês | MEDLINE | ID: mdl-31616059

12.

Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy.

Silkenstedt, Elisabeth; Arenas, Fabian; Colom-Sanmartí, Berta; Xargay-Torrent, Sílvia; Higashi, Morihiro; Giró, Ariadna; Rodriguez, Vanina; Fuentes, Patricia; Aulitzky, Walter E; van der Kuip, Heiko; Beà, Sílvia; Toribio, Maria L; Campo, Elias; López-Guerra, Mònica; Colomer, Dolors.

J Exp Clin Cancer Res ; 38(1): 446, 2019 Nov 01.

Artigo em Inglês | MEDLINE | ID: mdl-31676012

13.

Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA.

Heine, Simon; Kleih, Markus; Giménez, Neus; Böpple, Kathrin; Ott, German; Colomer, Dolors; Aulitzky, Walter E; van der Kuip, Heiko; Silkenstedt, Elisabeth.

J Hematol Oncol ; 11(1): 112, 2018 09 04.

Artigo em Inglês | MEDLINE | ID: mdl-30180865

BVS Violência e Saúde

Informação e Conhecimento para a Saúde

Configurar filtros

Sua seleção (0)

Formato de exportação:

Exportar:

B-cell non-Hodgkin lymphomas.

Mantle cell lymphoma-Update on molecular biology, prognostication and treatment approaches.

Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimus.

The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysis.

Mantle cell lymphoma - advances in molecular biology, prognostication and treatment approaches.

Mantle cell lymphoma-Advances in molecular biology, prognostication and treatment approaches.

Biological and Clinical Determinants Shaping Heterogeneity in Mantle Cell Lymphoma.

The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.

[Aggressive lymphoma (DLBCL, MCL) - what's new?] / Aggressive Lymphome (DLBCL, MCL) was ist neu?

PARP14 is a novel target in STAT6 mutant follicular lymphoma.

Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells.

Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy.

Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA.